Guggenheim analyst Debjit Chattopadhyay initiated coverage of Solid Biosciences (SLDB) with a Buy rating and $26 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences: De-Risking Duchenne Program and Advancing Gene Therapy Pipeline Supports Buy Rating and $19 Target
- Solid Biosciences files to sell 1.32M shares of common stock for holders
- Solid Biosciences files to sell 42.78M shares of common stock for holders
- Solid Biosciences reports Q4 EPS (53c), consensus (52c)
- Buy Rating on SGT-003 Driven by Best-in-Class Efficacy Signals, Improving Safety, and Accelerated Approval Optionality